In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease
- PMID: 21331071
- DOI: 10.1038/leu.2011.16
In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease
Abstract
Mature donor-derived T cells in allogeneic bone marrow (BM) transplants mediate the graft-versus-tumor (GVT) effect by recognizing alloantigens on leukemic cells. However, alloantigen reactivity towards non-malignant tissues also induces graft-versus-host disease (GVHD). Defining T-cell subpopulations that mediate the GVT effect in the absence of GVHD induction remains a major challenge in allogeneic BM transplantation. In this study, we show that in vitro-generated alloantigen-specific CD8(+) cytotoxic T cells (CTLs) established by weekly stimulation with alloantigen-expressing antigen-presenting cells did not induce GVHD in two major histocompatibility complex-mismatched BM transplantation models, where induction of lethal GVHD is dependent on the presence of either CD4(+) or CD8(+) T cells. Despite their strong alloantigen specificity, transplantation of CTLs did not induce the expression of GVHD-associated cytokines IFN-γ and TNF-α or clinical or histological signs of GVHD, and lead to a survival rate of above 90%. However, transplantation of unstimulated CD8(+) T cells, which were not primed by the alloantigen in vitro, induced GVHD in both the transplantation models. Although CTLs were impaired in GVHD induction, they efficiently eradicated Bcr-Abl-transformed B-cell leukemias or mastocytomas. Thus, in vitro-derived CTLs might be useful for optimizing anti-tumor therapy in the absence of GVHD induction.
Similar articles
-
Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.Bone Marrow Transplant. 2007 Sep;40(5):487-97. doi: 10.1038/sj.bmt.1705759. Epub 2007 Jul 2. Bone Marrow Transplant. 2007. PMID: 17603512
-
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.Transplantation. 2007 Feb 15;83(3):314-22. doi: 10.1097/01.tp.0000250725.95074.f1. Transplantation. 2007. PMID: 17297406
-
Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.Cancer Res. 2000 Oct 15;60(20):5797-802. Cancer Res. 2000. PMID: 11059776
-
The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.Leuk Lymphoma. 1999 May;33(5-6):409-20. doi: 10.3109/10428199909058446. Leuk Lymphoma. 1999. PMID: 10342569 Review.
-
Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.Front Immunol. 2018 Dec 19;9:2979. doi: 10.3389/fimmu.2018.02979. eCollection 2018. Front Immunol. 2018. PMID: 30631325 Free PMC article. Review.
Cited by
-
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.JCI Insight. 2020 Apr 23;5(8):e131099. doi: 10.1172/jci.insight.131099. JCI Insight. 2020. PMID: 32191634 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous